GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Common Stock

Destiny Pharma (LSE:DEST) Common Stock : £0.95 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Common Stock?

Destiny Pharma's quarterly common stock increased from Dec. 2022 (£0.73 Mil) to Jun. 2023 (£0.95 Mil) but then stayed the same from Jun. 2023 (£0.95 Mil) to Dec. 2023 (£0.95 Mil).

Destiny Pharma's annual common stock increased from Dec. 2021 (£0.60 Mil) to Dec. 2022 (£0.73 Mil) and increased from Dec. 2022 (£0.73 Mil) to Dec. 2023 (£0.95 Mil).


Destiny Pharma Common Stock Historical Data

The historical data trend for Destiny Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Common Stock Chart

Destiny Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.60 0.60 0.73 0.95

Destiny Pharma Semi-Annual Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.73 0.73 0.95 0.95

Destiny Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Destiny Pharma (LSE:DEST) Business Description

Traded in Other Exchanges
Address
Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB
Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines